F2 and hepatocellular carcinoma: In 1984, Liebman et al measured abnormal prothrombin by a competition radioimmunoassay using a conventional polyclonal antibody in the serum of 76 HCC cases and reported increased abnormal prothrombin in 69 (91%) cases; the level of these cases exceeded 300 ng ml−1 in 51 (67%) cases.